

**Amendments To The Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:


1. (Original) A method of treating diseases or conditions in a mammal, such as a human, disease or condition caused by low plasma apoA-1 levels which comprises the administration of a therapeutically effective amount of a LRH1 activator or salt, solvate or physiologically functional derivative thereof.

2. (Canceled)

3. (Currently amended) A method according to claim 1 ~~or a use according to claim 2 or use according to claim 2~~ wherein the LRH1 activator is a LRH1 agonist or salt, solvate or physiologically functional derivative thereof

4. (Currently amended) A method ~~or use~~ according to claim 3 wherein the LRH1 agonist is a selective agonist or salt, solvate or physiologically functional derivative thereof

5. (Currently amended) ~~Use according to claim 2 or a~~ A method according to claim 1 where the LHR1 activator is a compound according to formula (I) or salt, solvate or physiologically functional derivative thereof



6. (Currently amended) ~~Use of a~~ A method according to any preceding claim 1 wherein the disease or condition caused by low plasma apoA-1 levels is atherosclerosis, dyslipidemia, peripheral vascular disease, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, vascular complications of diabetes, obesity and endotoxemia.

7. (Original) A pharmaceutical formulation for use in the treatment of diseases or conditions caused by low plasma apoA-1 levels comprising a LRH1 activator or salt, solvate or physiologically functional derivative thereof together with at least one pharmaceutical carrier wherein the LRH1 activator is present in an amount effective for use in the treatment of diseases or conditions caused by low plasma apoA-1 levels.

8. (Original ) A method for identifying compounds that will be useful in treating diseases or conditions caused by low plasma apoA-1 levels comprising the step of determining whether the compound interacts directly with LRH1, or the step of determining whether the compound activates LRH1.

9. (Original) A method for treating diseases or condition caused by low plasma apoA-1 levels comprising administration of compounds or salts, solvates or physiologically functional derivatives thereof identified using the screening method of claim 7.

10-11 (Canceled)

12. (New) A method of upregulating apoA-1 expression levels *in vivo* which comprises the administration of an effective amount of an LRH1 activator or salt, solvate or physiologically functional derivative thereof.

13. (New) A method according to claim 12 where the LHR1 activator is a compound according to formula (I) or salt, solvate or physiologically functional derivative thereof

